Aimovig (erenumab-aooe) / Amgen, Novartis 
Welcome,         Profile    Billing    Logout  
 12 Diseases   17 Trials   17 Trials   2487 News 


«12...13141516171819202122232425»
  • ||||||||||  Journal:  The CGRP Pathway in Migraine as a Viable Target for Therapies. (Pubmed Central) -  Nov 11, 2019   
    To date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns. If ongoing long-term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.
  • ||||||||||  Review, Journal:  Antigens and Antibodies in Disease With Specifics About CGRP Immunology. (Pubmed Central) -  Nov 11, 2019   
    Specifics to CGRP ligand, receptor, antagonism, and molecules, small and large, complete this review. Completion will facilitate assessment of the similarities, differences, and application of the forthcoming anti-CGRP receptor and ligand antagonists for patients.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Aimovig (erenumab) / Amgen, Novartis
    Improvement in Cervical Radiculopathy by Erenumab During the Preventive Treatment of Migraine in a Patient with CKD () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5895;    
    She was taking pantoprazole, sacubitril/valsartan, metoprolol, clonidine, aspirin, linagliptin, pravastatin, alirocumab, denosumab, gabapentin, pentoxifylline, calcitriol, erythropoietin, sevelamer and pain medications including narcotics...This incidental finding may suggest additional use of CGRP-inhibitor for the treatment of radiculopathy. Therefore, further researches are necessary to prove this hypothesis.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Journal:  Erste Langzeitdaten zu Erenumab. (Pubmed Central) -  Oct 22, 2019   
    Therefore, further researches are necessary to prove this hypothesis. No abstract available
  • ||||||||||  Journal:  Emerging drugs for migraine treatment: an update. (Pubmed Central) -  Oct 16, 2019   
    Several more studies are needed to fully understand the clinical potential, long-term safety and cost-effectiveness of these therapies. This paramount achievement should stimulate the development of further research in the migraine field.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache (clinicaltrials.gov) -  Oct 6, 2019   
    P4,  N=687, Not yet recruiting, 
    Erenumab is an efficacious and well tolerated preventive treatment in adult patients with episodic and chronic migraine. Trial completion date: Feb 2022 --> May 2022 | Trial primary completion date: Aug 2021 --> Nov 2021
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment closed, Trial completion date, Trial primary completion date:  A Controlled Trial of Erenumab in Migraine Prevention (clinicaltrials.gov) -  Oct 3, 2019   
    P3,  N=261, Active, not recruiting, 
    Trial completion date: Feb 2022 --> May 2022 | Trial primary completion date: Aug 2021 --> Nov 2021 Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
  • ||||||||||  Symdeko (tezacaftor/ivacaftor) / Vertex, Fasenra (benralizumab) / AstraZeneca, Aimovig (erenumab) / Amgen, Novartis
    Journal:  Erenumab-aooe, Benralizumab, and Tezacaftor/ivacaftor. (Pubmed Central) -  Sep 20, 2019   
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Mar 2020 No abstract available
  • ||||||||||  Journal:  Role of CGRP in Migraine. (Pubmed Central) -  Sep 18, 2019   
    Small molecule CGRP receptor antagonists, gepants, are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (Eptinezumab, Fremanezumab, and Galcanezumab) or the CGRP receptor (Erenumab) effectively prevent migraine attacks. The neurobiology of CGRP signaling is briefly summarized together with key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatments.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment open:  OASIS (CM): Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (clinicaltrials.gov) -  Sep 9, 2019   
    P3,  N=286, Recruiting, 
    The neurobiology of CGRP signaling is briefly summarized together with key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatments. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Drug updates and approvals: 2018 in review. (Pubmed Central) -  Sep 8, 2019   
    In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment open:  DRAGON: Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (clinicaltrials.gov) -  Sep 4, 2019   
    P3,  N=550, Recruiting, 
    This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya). Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  CGRP as the target of new migraine therapies - successful translation from bench to clinic. (Pubmed Central) -  Aug 30, 2019   
    We describe the biology of CGRP signalling, summarize key clinical evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system. Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiology of migraine.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
    Journal:  CGRP Antibodies as Prophylaxis in Migraine. (Pubmed Central) -  Aug 30, 2019   
    Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Drug-Induced Colitis as a Side Effect of Calcitonin Gene-Related Peptide (CGRP) Antagonist for Migraines (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_1525;    
    In May 2018, an injectable calcitonin gene-related peptide (CGRP) antagonist, erenumab, was approved by the FDA for migraine prophylaxis...Once those patients that are more at risk are identified, there may be a role for endoscopic surveillance in certain patients taking these medications. While drug-induced colitis is likely to be an uncommon manifestation of blocking CGRP, clinicians should be aware of this potential side effect of targeted therapy and counsel patients receiving this therapy.
  • ||||||||||  Emgality (galcanezumab) / Eli Lilly, Aimovig (erenumab) / Amgen, Novartis
    Journal:  Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. (Pubmed Central) -  Aug 6, 2019   
    P2, P3
    While drug-induced colitis is likely to be an uncommon manifestation of blocking CGRP, clinicians should be aware of this potential side effect of targeted therapy and counsel patients receiving this therapy. In this small, self-selected cohort, the results indicate a therapeutic effect of monoclonal antibodies targeting the CRGP pathway in chronic migraine prevention after treatment termination up to 12 weeks.